ArticleScientific reports2026
SoleFusion-Net: an explainable multimodal deep learning framework for diabetic foot syndrome classification in type II diabetes mellitus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of diabetic neuropathy remains a challenge due to reliance on subjective clinical assessments. We propose SoleFusion-Net, an explainable multimodal deep learning framework that integrates plantar pressure images with structured clinical data through an late-fusion dual-branch architecture. The image branch employs convolutional layers to extract biomechanical pressure features, while the tabular branch processes clinical and demographic variables. Learned representations are fused for joint classification. Extensive explainability techniques, including Grad-CAM, SHAP, surrogate decision trees, and prototyped critique analysis, were implemented to enhance transparency and clinician trust. Evaluated on 504 patients stratified into mild, moderate, and severe neuropathy, SoleFusion-Net achieved 83% validation accuracy with AUCs of 0.962, 0.892, and 0.933 across the three classes. Explainability analyses identified vibration perception threshold and monofilament scores as critical predictors, while Grad-Cam highlighted spatially significant plantar regions. SoleFusion-Net showcases the feasibility of adjusting the standard multimodal fusion process and the use of various XAI methods to achieve the goal of diabetic foot syndrome classification. Therefore, this solution ensures a trustworthy help about risk stratification. The framework provides a modular and explainable AI model for integrating multimodal biomedical data, with a structure that is potentially generalizable to other settings pending external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.